Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$1.64 - $3.3 $3,407 - $6,857
-2,078 Closed
0 $0
Q1 2022

May 10, 2022

BUY
$2.13 - $3.24 $4,426 - $6,732
2,078 New
2,078 $6,000
Q4 2021

Feb 11, 2022

SELL
$2.85 - $6.58 $32,652 - $75,387
-11,457 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$6.63 - $9.39 $2,797 - $3,962
422 Added 3.82%
11,457 $81,000
Q2 2021

Aug 09, 2021

BUY
$8.98 - $11.6 $99,094 - $128,006
11,035 New
11,035 $101,000
Q4 2020

Feb 09, 2021

SELL
$7.78 - $12.13 $4,551 - $7,096
-585 Closed
0 $0
Q3 2020

Nov 02, 2020

SELL
$9.5 - $11.14 $8,968 - $10,516
-944 Reduced 61.74%
585 $5,000
Q2 2020

Aug 11, 2020

BUY
$7.01 - $13.24 $4,206 - $7,944
600 Added 64.59%
1,529 $15,000
Q1 2020

May 15, 2020

SELL
$6.28 - $14.57 $25,302 - $58,702
-4,029 Reduced 81.26%
929 $8,000
Q4 2019

Feb 13, 2020

BUY
$6.5 - $10.73 $20,273 - $33,466
3,119 Added 169.6%
4,958 $43,000
Q3 2019

Oct 17, 2019

BUY
$8.75 - $12.85 $10,106 - $14,841
1,155 Added 168.86%
1,839 $20,000
Q2 2019

Aug 05, 2019

BUY
$12.3 - $35.76 $7,146 - $20,776
581 Added 564.08%
684 $9,000
Q1 2019

Apr 16, 2019

SELL
$20.77 - $42.37 $768 - $1,567
-37 Reduced 26.43%
103 $4,000
Q4 2018

Jan 17, 2019

BUY
$20.07 - $46.7 $321 - $747
16 Added 12.9%
140 $3,000
Q3 2018

Nov 02, 2018

BUY
$41.2 - $59.85 $1,936 - $2,812
47 Added 61.04%
124 $0
Q2 2018

Jul 24, 2018

BUY
$48.3 - $68.25 $3,719 - $5,255
77 New
77 $0
Q1 2018

May 03, 2018

SELL
$59.7 - $99.25 $21,850 - $36,325
-366 Closed
0 $0
Q4 2017

Feb 02, 2018

BUY
$93.85 - $132.45 $26,090 - $36,821
278 Added 315.91%
366 $37,000
Q3 2017

Oct 20, 2017

BUY
$72.0 - $119.75 $6,336 - $10,538
88
88 $11,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $149M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.